Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Treasury Shares: 2018-2025

Historic Treasury Shares for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to $94,375.

  • Autolus Therapeutics' Treasury Shares rose 160.81% to $94,375 in Q3 2025 from the same period last year, while for Sep 2025 it was $94,375, marking a year-over-year increase of 160.81%. This contributed to the annual value of $32,412 for FY2024, which is 72.16% down from last year.
  • Autolus Therapeutics' Treasury Shares amounted to $94,375 in Q3 2025, which was up 480.77% from $16,250 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Treasury Shares high stood at $80.0 billion for Q3 2021, and its period low was $16,250 during Q1 2025.
  • Its 3-year average for Treasury Shares is $49,942, with a median of $39,046 in 2024.
  • As far as peak fluctuations go, Autolus Therapeutics' Treasury Shares slumped by 100.00% in 2021, and later skyrocketed by 160.81% in 2025.
  • Autolus Therapeutics' Treasury Shares (Quarterly) stood at $1.5 million in 2021, then plummeted by 100.00% to $1.2 million in 2022, then reached $116,436 in 2023, then plummeted by 72.16% to $32,412 in 2024, then skyrocketed by 160.81% to $94,375 in 2025.
  • Its Treasury Shares was $94,375 in Q3 2025, compared to $16,250 in Q2 2025 and $16,250 in Q1 2025.